Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.

Suzanne L. Topalian,Shailender Bhatia,Asim Amin,Ragini R. Kudchadkar,William H. Sharfman,Celeste Lebbe,Jean-Pierre Delord,Lara Dunn,Michi M. Shinohara,Rima M. Kulikauskas,Christine H. Chung,Uwe M. Martens,Robert L. Ferris,Julie E Stein,Elizabeth L. Engle,Lot A. Devriese,Christopher D. Lao,Junchen Gu,Bin Li,Tian Chen,Adam Barrows,Andrea Horvath,Janis M. Taube,Paul Nghiem

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.

2020

PURPOSEMerkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunos...

Keywords:

Merkel cell polyomavirus
Cancer research
Nivolumab
Medicine
Skin cancer
Merkel cell carcinoma
basal cell
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations